Tidepath

More GLP-1 drugs

Albiglutide

Also called Tanzeum, Eperzan

A weekly GLP-1 shot that its maker stopped selling worldwide, saying the reasons were commercial346.

Status
Approved by the FDA in 2014 for type 2 diabetes, as Tanzeum, and now listed by the FDA as discontinued37.
How it's taken
By injection

What it is

Tanzeum, called Eperzan in Europe, is albiglutide, a GLP-1 drug14. GLP-1 is a hormone your gut releases when you eat2. Albiglutide acts on the same receptor: it raises insulin when blood sugar is high and slows how fast the stomach empties1. It's built from two copies of a slightly changed human GLP-1, joined end to end and fused to human albumin, a protein found in blood1. The change protects it from an enzyme, DPP-4, that breaks GLP-1 down, and the albumin part, together with that protection, makes it last longer1. Its half-life, the time it takes for half a dose to clear, is about 5 days, which made once-a-week injections possible1. It came as a powder inside the pen, mixed with liquid before each injection1. It was approved to improve blood sugar in adults with type 2 diabetes14.

What makes it distinct

Its maker, GSK, decided in 2017 to stop selling it worldwide, and said the decision was commercial and not about safety or effectiveness56.

What the evidence shows

Tanzeum was tested in 8 phase 3 trials in adults with type 2 diabetes1. They compared it with placebo, a dummy treatment, and with several other diabetes medicines, and measured HbA1c, a blood test of average blood sugar over the past few months1. Against placebo, HbA1c fell more on Tanzeum1. Harmony Outcomes, a heart-outcomes trial paid for by GSK and published in 2018, enrolled 9,463 adults aged 40 and over with type 2 diabetes and heart or blood vessel disease8. Fewer people had a major heart event (a heart attack, a stroke, or death from heart or blood vessel disease) on albiglutide than on placebo8.

Open questions

  • Whether it causes thyroid tumors in people. Its label said this was unknown1. Other GLP-1 drugs have caused thyroid C-cell tumors (tumors of C-cells, a type of cell in the thyroid) in rodents, but albiglutide's own cancer risk couldn't be tested in rodents, because the animals quickly made antibodies that cleared the drug1.
  • Longer-term effects. Harmony Outcomes followed people for a median (the middle value) of 1.6 years8.

Worth knowing

The FDA lists Tanzeum as discontinued, with its license voluntarily revoked37. In the EU, Eperzan's approval was withdrawn in October 2018 at GSK's request, for commercial reasons4.

Sources

  1. TANZEUM (albiglutide) for injection, prescribing information, GlaxoSmithKline (FDA, revised December 2017)
  2. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018 (PubMed 29617641)
  3. Drugs@FDA: BLA 125431, TANZEUM (albiglutide)
  4. European Medicines Agency: Eperzan (albiglutide) EPAR, withdrawn
  5. GSK Q2 2017 results, presentation transcript (July 2017)
  6. GSK Dear Healthcare Professional letter: Eperzan (albiglutide) global discontinuation, 9 September 2017 (hosted on GOV.UK)
  7. FDA Purple Book monthly data download, September 2026
  8. Hernandez AF et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes). Lancet. 2018 (PubMed 30291013)

More in More GLP-1 drugs